Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.

PSMA-Targeted PET Imaging and Radioligand Therapy in the Management of Prostate Cancer

May 16, 2024 | 3:30 p.m. ET

The webinar will cover the background of molecular imaging and PSMA-PET and discuss both OSPREY and CONDOR study designs and topline results. Dr. Rowe will share and discuss interesting case studies from his over 3 years’ experience using PSMA-targeted PET imaging to demonstrate the role of PSMA-PET in informing treatment decisions both at the initial staging of men with high risk disease, as well as in the recurrent setting as well as discussing the prognostic value of PSMA-PET. The session will end with a discussion on Radiomics and how AI may help facilitate image interpretation and could play a role in patient education.

This webinar was developed and sponsored by Lantheus and is intended for healthcare professionals only.

Steven Rowe, MD, PhD

Steven Rowe, MD, PhD

Professor and Chief of Molecular Imaging and Therapeutics Division, University of North Carolina School of Medicine - Radiology

Steven Rowe, M.D., Ph.D., is Professor and Chief of the Molecular Imaging and Therapeutics Division in the UNC School of Medicine Department of Radiology. Dr. Rowe received his medical degree and Ph.D. in chemistry from the University of Michigan. He completed residencies in radiology and nuclear medicine at Johns Hopkins University School of Medicine. Most recently, he was an Associate Professor of Radiology and Radiological Science at Johns Hopkins University in Baltimore, Maryland.

He clinically focuses on nuclear medicine, and his research work has been centered around applications of novel molecular imaging agents for positron emission tomography (PET) and single-photon emission computed tomography (SPECT). He is particularly interested in the use of prostate-specific membrane antigen (PSMA)-targeted PET agents in prostate cancer and renal cell carcinoma, as well as the clinical utilization of 99mTc-sestamibi SPECT for non-invasive characterization of renal masses. He and his colleagues recently developed and validated a structured reporting system for delineating and codifying findings on PSMA PET known as PSMA Reporting and Data System (PSMA-RADS).

Presented by: